modelP02DA01
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Niclosamide | |
| ATC code: | P02DA01 | route: | oral |
| compartments: | 1 | |
| dosage: | 2000 | mg |
| volume of distribution: | 0.16 | L |
| clearance: | 2.12 | L/h |
| other parameters in model implementation | ||
Niclosamide is an anthelmintic drug primarily used to treat tapeworm infections in humans, approved for use in many countries since the 1960s. It is listed on the WHO Model List of Essential Medicines. Recently, it has gained renewed interest for repurposing against other conditions, including viral infections and cancer.
Pharmacokinetics
Single oral administration in healthy adult volunteers; pharmacokinetics reported after 2 g oral dose.
References
Schweizer, MT, et al., & Yu, EY (2018). A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PloS one 13(6) e0198389–None. DOI:10.1371/journal.pone.0198389 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29856824
Marcelín-Jiménez, G, et al., & García-González, A (2012). Development of a method by UPLC-MS/MS for the quantification of tizoxanide in human plasma and its pharmacokinetic application. Bioanalysis 4(8) 909–917. DOI:10.4155/bio.12.41 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22533565
Senkowski, W, et al., & Fryknäs, M (2015). Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer. Molecular cancer therapeutics 14(6) 1504–1516. DOI:10.1158/1535-7163.MCT-14-0792 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25911689
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)